Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -113.63M |
| Shares Out | 37.60M |
| EPS (ttm) | -3.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 486,127 |
| Open | 40.05 |
| Previous Close | 40.82 |
| Day's Range | 38.62 - 40.72 |
| 52-Week Range | 19.38 - 87.24 |
| Beta | 2.23 |
| Analysts | Strong Buy |
| Price Target | 86.21 (+115.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 86.21, which is an increase of 114.99% from the latest price.
News
Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time
What's Happening With Axsome Therapeutics Stock?
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company...
Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
$100 million now available upon the potential FDA approval of AXS-05
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
These stocks are expected to put up big gains in a short amount of time.
Why Axsome Therapeutics Stock Rocketed Higher This Week
Optimism among investors is growing for the possible approval of the biotech's MDD drug.
1 Beaten-Down Stock With 10X Potential
This biotech is down, but it isn't out just yet.
Why Axsome Therapeutics Stock Caught Fire in September
This beaten-down biotech regained some lost ground last month.
SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $...
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics, In...
2 Best Biotech Stocks to Buy Right Now
Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.
Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Why Wall Street Thinks This Biotech Stock Can Triple Your Money
The risks are huge, but so are the potential returns.
Axsome Therapeutics Stock Rises 36% In A Month But Will The Rally Continue?
A couple of months back we discussed that Axsome Therapeutics stock is likely to rebound after it fell nearly 20% in a month following the U.S. FDA's decision to pull the breakthrough therapy designatio...
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders...
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Axsome Therapeutics Inc Ranked Among Today's Top Shorts After The European Central Bank Says It May Slow Down Bond Pu...
The Dow Jones dipped about 40 points, the S&P 500 was flat, and the Nasdaq saw some mild gains, led by Big Tech stocks such as Apple, Facebook, and Amazon. Find opportunities in today's market with the ...
Why Axsome Therapeutics Stock Cratered in August
An unexpected regulatory setback weighed heavily on the biotech's shares last month.
Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
3 Healthcare Stocks That Might Skyrocket When COVID Is Over
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?
3 Biotech Stocks Wall Street Expects to Double Soon
All three stocks on this list can more than double your money according to investment bank analysts who cover them.
Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay?
There are still plenty of unknowns related to Axsome's FDA filing.
3 Biotech Stocks That Are Too Cheap to Ignore
You'll definitely want to check out these biotech bargains.
Here's Why Axsome Therapeutics Stock Is Surging Today
The company still doesn't have much to say about the FDA and its experimental new anti-depression drug.
Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.